When the United Kingdom's Tobacco and Vapes Bill receives royal assent next week, it will do something no major economy has achieved at scale before: it will use the law to permanently remove a generation of people from the pool of future smokers. Children who are 17 or younger today - and everyone born after them - will never legally be able to buy a cigarette in Britain. Not when they turn 25. Not when they turn 50. Not ever.
For public health advocates, this is the headline. For Canada's insurance industry, and for the provincial governments that bear the direct cost of tobacco-related illness, the implications run considerably deeper, and considerably longer.
Insurance is, at its core, a business of predicting who will get sick, when, and at what cost. Smoking has been one of the most reliable predictors actuaries have ever had. The data is unambiguous and has been for decades: smokers die younger, develop costly chronic diseases at higher rates, and draw far more heavily on health and long-term care resources than non-smokers.
In Canada, the numbers are striking. According to Health Canada, tobacco is responsible for an estimated $5.43 billion in health care-related costs and $5.25 billion in lost productivity costs due to premature death and long-term disability every year. A Conference Board of Canada analysis - the most comprehensive national cost study available, based on 2012 data - estimated the total economic cost, including health care, forgone earnings, disability, and enforcement, at more than $16 billion annually. Smoking kills approximately 45,000 Canadians each year, accounting for roughly 18 per cent of all deaths in the country. In the province of Ontario alone, direct health care costs attributable to smoking are estimated at $2.7 billion annually.
The British legislation does not make these costs disappear overnight. The cohort affected by the ban — those born on or after January 1, 2009, who will never be permitted to buy tobacco — are still children or teenagers. Their impact on insurance loss ratios, on mortality tables, on provincial drug benefit programmes and long-term care costs, will not be felt meaningfully for another ten, twenty, even thirty years. Actuaries are accustomed to thinking in those timescales. And when they do, the mathematics are striking.
If you model a generation in which smoking prevalence falls to near zero — not through gradual social change, but through a legal floor that prevents uptake entirely — the downstream effects on life insurance mortality, on critical illness payouts, on group benefits claims for lung cancer, heart disease, and chronic obstructive pulmonary disease, are enormous.
A cohort that does not smoke at all is a cohort that, on average, lives longer, spends less time in hospital, draws less on provincial drug plans and long-term care, and generates fewer large catastrophic claims in the middle decades of life.
For Canadian life insurers, this represents a significant long-term opportunity. Premiums calibrated against a genuinely lower-risk population translate into healthier margins or more competitive pricing, or both. For group benefits carriers and self-insured employers, the long-run claims trajectory bends downward. Smoking causes roughly one in five deaths in Canada annually. Even a partial, generational reduction in that figure reshapes the actuarial landscape in ways that would take decades to fully price.
The key word, of course, is generational. No chief actuary at Manulife, Sun Life, or Great-West Lifeco is revising their 2027 loss projections on the basis of a British law passed this week. But the insurers and reinsurers who are already beginning to model what a structurally lower-smoking population looks like - and pricing long-tail products accordingly - will have a significant informational advantage over those who are not.
The actuarial implications of a genuine smoke-free generation are not purely theoretical - and Canadian researchers have already done some of the modelling. A January 2025 study published in the journal Health Promotion and Chronic Disease Prevention in Canada, authored by health economist Dr. Doug Coyle of the University of Ottawa, assessed the long-term impacts of a smoke-free generation policy applied to Canada. Coyle's model found that after 50 years, such a policy would lead to nearly 477,000 more quality-adjusted life years for Canadians, along with $2.3 billion in reduced health care costs. The work makes clear that while there would be offsetting revenue losses - $7.4 billion less in smoking-related taxes - the combined value of the health gains and health care cost savings would outweigh those losses substantially.
This is meaningful for Canadian insurers in a very direct way. Unlike their American counterparts, who operate alongside a patchwork of private and public coverage, Canadian life and group benefits insurers write products for a population whose health care costs are largely borne by provincial governments. The interaction between public and private coverage means that any structural reduction in smoking prevalence generates savings across multiple balance sheets simultaneously: provincial health ministries, provincial drug plans, and private carriers all stand to benefit. Ontario's Ministry of Health, the country's largest provincial payer, spends billions annually on smoking-attributable conditions. Alberta, British Columbia, and Quebec are in similar positions.
There is a further, very recent data point that makes this argument concrete in a way that no actuarial model can quite match. In March 2025, an Ontario court approved the largest legal settlement in Canadian history: a $32.5 billion agreement requiring three major tobacco companies - JTI-Macdonald, Rothmans Benson & Hedges, and Imperial Tobacco Canada - to compensate provincial and territorial governments, as well as individual smokers, for decades of smoking-related health costs. Payments began flowing to the provinces in August 2025 and will continue for the next 18 years. Ontario alone received $1.8 billion in the first tranche. The settlement is, in effect, a court-endorsed valuation of the cost of a generation of smokers to Canada's health system. For Canadian insurers making the case that reducing smoking prevalence is worth proactive legislative action, that number - $32.5 billion - is the most powerful single data point available.
The British data will also become genuinely useful for Canadian carriers writing long-tail life products - 30-year term policies, whole life, universal life - within the next fifteen years. If UK mortality data begins to diverge from Canadian mortality data in the ways the actuarial models predict, driven in part by structural differences in smoking prevalence, that divergence will inform reinsurance pricing, product design, and underwriting philosophy on this side of the Atlantic.
Read next: The Best Insurance Brokers in Canada
There is also an immediate practical consideration for Canadian group benefits carriers and the employers who rely on them. Unlike the United States, Canada does not permit premium surcharges for smokers in its provincial health insurance systems — the principle of universal coverage prevents that. But in the private market, the picture is starkly different. Canadian life insurers routinely charge smokers between 1.5 and 3 times the premiums paid by non-smokers for equivalent coverage, based on cotinine testing and self-disclosure. The vaping classification question — whether e-cigarette users are rated as smokers — remains unsettled and varies by carrier, a parallel to the challenges facing UK and Australian insurers as the nicotine landscape fragments.
If UK population data begins to demonstrate measurable improvements in health claims and mortality over the next decade - even early signals, given the relatively young age of the protected cohort - it will strengthen the case for more proactive smoking-related underwriting tools in the Canadian private market, and potentially for renewed provincial advocacy around tobacco endgame policies.
Canada is closer to this idea than most people realise, and the political terrain is more navigable than it might appear.
Health Canada has set an ambitious tobacco endgame goal: reducing smoking prevalence to less than five per cent by 2035, colloquially known as the "<5 by '35" target. The 2025 federal report Delivering Results: Advancing Canada's Tobacco Strategy confirms that this goal remains active policy.
As of 2024, approximately 11 per cent of adult Canadians smoke — meaning the gap between current prevalence and the endgame target remains significant. Incremental measures alone may not close it. Several tobacco control researchers, including those at the Ontario Tobacco Research Unit and the BC Lung Foundation, have explicitly recommended a smoke-free generation policy as a necessary component of reaching that target.
Dr. Coyle's modelling was not purely academic. It was published in a government journal, cited by Health Canada researchers, and framed explicitly as a policy analysis. The federal government is aware of the option. Several provincial health advocacy organisations — particularly in British Columbia, where the BC Lung Foundation has campaigned actively for a smoke-free generation policy — have pressed for legislative action. The political environment post-2025 federal election, with a Carney Liberal government that has emphasised health system investment and youth nicotine protection, may offer a more receptive audience for bold tobacco control measures than previous federal governments — though no specific smoke-free generation legislation has yet been signalled.
The barriers are real but not insurmountable. The federal government has clear constitutional authority over the sale and marketing of tobacco products under the Tobacco and Vaping Products Act of 2018 - the legislative vehicle is already in place, and amending it to include a rolling-age sales ban would require political will more than legal innovation. The tobacco industry retains lobbying influence and would certainly challenge such a measure, as it did in New Zealand before that country's complete repeal of its own smoke-free generation law in 2024. The illicit tobacco market, which already accounts for an estimated 10 to 20 per cent of Canada's tobacco sales, would likely expand in the short term - a concern that has complicated the policy debate here as it did in New Zealand.
But the New Zealand cautionary tale has a different lesson than it is sometimes presented as having. The law there was repealed not because it was unworkable or opposed by a majority of New Zealanders — polls showed 60 per cent opposed its repeal - but because it became a bargaining chip in coalition negotiations, traded for unrelated tax cuts. Canada's parliamentary structure and the federal government's unilateral jurisdiction over tobacco regulation make that kind of backroom reversal considerably less likely. The British law, passed with broad cross-party support in a parliament where the governing party holds a significant majority, provides a more durable template.
For Canada's insurance industry, the more immediately actionable question may not be whether federal legislation will replicate the British approach, but whether insurers should be more actively supporting it. The industry has a direct, quantifiable financial interest in reducing smoking prevalence - an interest that is arguably larger and more sustained than that of almost any other private sector actor. Trade bodies such as the Canadian Life and Health Insurance Association have generally supported tobacco control measures, but the industry has not historically positioned itself as a leading voice for aggressive legislative intervention. The UK precedent - and the domestic modelling from Dr. Coyle's research - gives Canadian insurers a concrete, evidence-based argument for why the long-term mathematics favour bold action.
Canada's smoke-free generation is a policy option, not a distant fantasy. Whether the political will to pursue it materialises is a question for Parliament and the provinces. But the actuarial case is already made.
